Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) closed at $855.35 in the latest trading session, marking a +1.14% move from the prior day. This change outpaced the S&P 500's 0.28% loss on the day. At the same time, the Dow lost 0.52%, and the tech-heavy Nasdaq lost 0.08%. Shares of the drugmaker have appreciated by 12.07% over the course of the past month, outperforming the Medical sector's gain of 3.31%, and the S&P 500's gain of 4.03%.The investment community will be closely monitoring the performance of Eli Lilly in its forthcoming earnings report. The company is scheduled to release its earnings on October 30, 2025. The company's upcoming EPS is projected at $6.38, signifying a 440.68% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $16.06 billion, indicating a 40.38% increase compared to the same quarter of the previous year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $22.95 per share and revenue of $61.72 billion, indicating changes of +76.67% and +37.03%, respectively, compared to the previous year. Investors should also note any recent changes to analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.26% lower. Currently, Eli Lilly is carrying a Zacks Rank of #3 (Hold). From a valuation perspective, Eli Lilly is currently exchanging hands at a Forward P/E ratio of 36.85. This indicates a premium in contrast to its industry's Forward P/E of 14.65. One should further note that LLY currently holds a PEG ratio of 1.19. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry had an average PEG ratio of 1.59 as trading concluded yesterday. The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 59, this industry ranks in the top 24% of all industries, numbering over 250. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks